HDAC inhibitors, which can inhibit the activity of HDAC enzymes, have been extensively
studied in tumor immunotherapy and have shown potential therapeutic effects in cancer …

Nanomedicine in oncology has not had the success in clinical impact that was anticipated in
the early stages of the field's development. Ideally, nanomedicines selectively accumulate in …

Biofabrication techniques enable the performance of bioinspired three‐dimensional (3D)
matrices resembling primary tumors. To validate their reliability, embedded cells may …

Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) have rapidly
received Food and Drug Administration (FDA) approval as a new type of therapy for patients …

With the increasing knowledge of cancer pathophysiology, new therapeutics based on the
modulation of the immune system have been developed, overcoming many of the …

Navigating the intricate landscape of the tumor microenvironment (TME) unveils a pivotal
arena for cancer therapeutics, where cytokines and soluble mediators emerge as double …

Abstract Background Tumour-associated macrophages (TAMs) are an important component
of the tumour microenvironment (TME). However, the crosstalk between oesophageal …

Tumor immunotherapy has become a research hotspot in cancer treatment, with
macrophages playing a crucial role in tumor development. However, the tumor …

Lipid nanoparticles (LNPs) are biocompatible drug delivery systems that have found
numerous applications in medicine. Their versatile nature enables the encapsulation and …

Neuroblastoma (NB) is the most common extracranial solid pediatric cancer, and is one of
the leading causes of cancer-related deaths in children. Despite the current multi-modal …